Risk of Infection and IVIG Use

EP: 1.Review of Latest Guidelines on Quad Therapy in NDMM

EP: 2.Classifying High-Risk Patients With NDMM

EP: 3.Pretesting Prior to Quad Therapy for NDMM

EP: 4.Overview of the ADVANCE Study: Methodology and Design

EP: 5.Expert Perspectives on the Design of the ADVANCE Trial

EP: 6.Key Efficacy Results From ADVANCE: MRD Negativity Stratified by Age and Risk

EP: 7.Transplant Eligible vs Ineligible: Clinical Implications

EP: 8.Safety Signals of Daratumumab + KRd: Real-World Translation

Now Viewing

EP: 9.Risk of Infection and IVIG Use

EP: 10.Final Thoughts and Future Innovations

Panelists discuss how infection risk remains a significant concern in newly diagnosed multiple myeloma (NDMM), particularly with immunosuppressive regimens such as daratumumab-based combinations. They share strategies for prevention and management, including vaccination, prophylaxis, and selective use of intravenous immunoglobulin (IVIG), in patients with recurrent infections or hypogammaglobulinemia. They emphasize balancing infection control with therapy intensity, noting that proactive management can sustain treatment continuity and improve outcomes.